Akcea Therapeutics Inc buy tamam
Zusammenfassung
Diese Einschätzung wurde am 04.11.19 mit einem Endkurs von - beendet. Die BUY Einschätzung von tamam schloss unverändert vom Startkurs. tamam hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Akcea Therapeutics Inc | - | - | - | - |
| iShares Core DAX® | -3,03 % | -0,01 % | 11,95 % | 15,61 % |
| iShares Nasdaq 100 | -3,55 % | -2,55 % | 30,13 % | 44,54 % |
| iShares Nikkei 225® | -3,94 % | 2,18 % | 11,74 % | 8,35 % |
| iShares S&P 500 | -1,52 % | -0,88 % | 25,75 % | 42,39 % |
Kommentare von tamam zu dieser Einschätzung
In der Diskussion Akcea Therapeutics Inc diskutieren
Akcea Therapeutics received a positive vote from the FDA advisory panel
Recently, it was announced that Ionis Pharmaceuticals and Akcea Therapeutics received a positive vote from the FDA advisory panel. This bodes well for FDA approval of volanesorsen, because the panel vote came in better than expected. The FDA doesn't have to listen to the panel's vote, but it sure does help that the panel was in favor of the drug. For that reason, I believe that Ionis is a good buy.
Ionis and Akcea obtain a favorable outcome from an advisory panel with a vote of 12 "for" and 8 "against" approval of volanesorsen.
The FDA will likely approve volanesorsen on the premise that a REMS is implemented in order to cover itself on the thrombocytopenia issue.
Lately a host of biotechs have had their applications rejected only to be accepted several weeks later due to the FDA being more lenient on the drug approval process.
Ionis stands to gain big on FDA approval for volanesorsen because it stands to obtain milestone payments from Akcea, and it owns 68% of Akcea Therapeutics as well.
Ionis also has its licensing deal set with Akcea for inotersen which is going up for U.S. regulatory review either late this year or early next year to treat patients with hereditary transthyretin amyloidosis ((hATTR)).